With more than 90 approved drugs by 2020, therapeutic antibodies have played a central
role in shifting the treatment landscape of many diseases, including autoimmune disorders …

Antibody therapeutics continue to represent a significant portion of the biotherapeutic
pipeline, with growing promise for bispecific antibodies (BsAbs). BsAbs can target 2 different …

Mathematical models are increasingly being developed and calibrated in tandem with data
collection, empowering scientists to intervene in real time based on quantitative model …

In vitro affinity maturation of therapeutic monoclonal antibodies is commonly applied to
achieve desired properties, such as improved binding kinetics and affinity. Currently there …

For therapeutic biologics against soluble ligands, the magnitude and duration of target
suppression affect their therapeutic efficacy. Many factors have been evaluated in relation to …

Guiding the dose selection for monoclonal antibody oncology drugs is often done using
methods for predicting the receptor occupancy of the drug in the tumor. In this manuscript …

Early assessment of dosing requirements should be an integral part of developability
assessments for a discovery program. If a very high dose is required to achieve the desired …

Abstract System based pharmacokinetic (PK) models can be used to study and predict the
distribution of antibody based drugs into target tissues and assess the pharmacobinding …

Quantitative modeling is increasingly utilized in the drug discovery and development
process, from the initial stages of target selection, through clinical studies. The modeling can …

Affinity (KD) optimization of monoclonal antibodies is one of the factors that impacts the
stoichiometric binding and the corresponding efficacy of a drug. This impacts the dose and …